Overview

ACE-536 Extension Study - Myelodysplastic Syndromes

Status:
Completed
Trial end date:
2020-05-18
Target enrollment:
Participant gender:
Summary
Study A536-05 is an open-label extension study for patients previously enrolled in study A536-03 (ClinicalTrials.gov Identifier NCT01749514), to evaluate the long-term safety and tolerability of ACE-536 in patients with low or intermediate-1 risk MDS.
Phase:
Phase 2
Details
Lead Sponsor:
Acceleron Pharma Inc.
Acceleron Pharma, Inc.
Treatments:
Luspatercept